Compare BioNano Genomics Inc (BNGO) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Schwab US Dividend Equity ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Schwab US Dividend Equity ETF trades at $34.1. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SCHD | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $34.27 |
52-Week Low | $1.06 | $26.44 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
SCHD trades at $34.11, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is a core holding for dividend investors, highlighted by a recent $0.25 dividend declaration for June 2026. Media coverage emphasizes its role in retirement income strategies, though some articles note performance gaps versus peers like VYM.
Outlook remains stable for income-focused investors, with SCHD offering reliable dividends amid market rotations. Risks include interest rate sensitivity and tax inefficiencies in taxable accounts. Institutional interest persists, as seen in Barry Investment Advisors' 29.9% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
